levodopa has been researched along with mavoglurant in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Destee, A; Gao, H; Graf, A; Hattori, N; Hauser, RA; Kenney, C; Lang, AE; Merschhemke, M; Nagel, J; Poewe, W; Rascol, O; Stacy, M; Stocchi, F; Tolosa, E; Trenkwalder, C | 1 |
| Dronamraju, N; Graf, A; Hauser, RA; Kenney, C; Kumar, R; Merschhemke, M; Mostillo, J | 1 |
| Auladell, C; Beas-Zarate, C; Camins, A; Canudas, AM; de Lemos, ML; Folch, J; Lazarowski, A; Pallàs, M; Pedros, I; Petrov, D | 1 |
| Bilbe, G; Bouhelal, R; Desrayaud, S; Enz, A; Flor, PJ; Gasparini, F; Kuhn, R; McAllister, K; Ofner, S; Vranesic, I | 1 |
| Dronamraju, N; Graf, A; Kenney, C; Poewe, W; Shah, A; Stocchi, F; Trenkwalder, C; von Raison, F | 1 |
| Ahmed, H; Aziz, MAE; Bahbah, EI; Ebada, MA; Fala, SY; Ghaith, HS; Negida, A | 1 |
2 review(s) available for levodopa and mavoglurant
| Article | Year |
|---|---|
Mavoglurant as a treatment for Parkinson's disease.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Quality of Life; Receptor, Metabotropic Glutamate 5 | 2014 |
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis.
Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease | 2021 |
3 trial(s) available for levodopa and mavoglurant
| Article | Year |
|---|---|
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Indoles; International Cooperation; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors | 2013 |
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Early Termination of Clinical Trials; Excitatory Amino Acid Antagonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Kainic Acid; Sample Size; Severity of Illness Index; Tremor | 2016 |
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2016 |
1 other study(ies) available for levodopa and mavoglurant
| Article | Year |
|---|---|
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Half-Life; High-Throughput Screening Assays; Humans; Hyperthermia, Induced; Indoles; Levodopa; Male; Mice; Protein Binding; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |